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or improvement during the follow-up. Despite negative results of an examination of their BAL fluid,
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We assessed the negative predictive value of bronchoalveolar lavage (BAL) for Pneumocystis 
carinii pneumonia (PCP) during prophylaxis with aerosolized pentamidine. On the basis of the 
assumption that undiagnosed and untreated PCP would progress and become clinically appar- 
ent, for 3 months we prospectively followed 34 consecutive cases in which BAL had not detected 
PCP. All patients were immunodeficient, had a symptomatic human immunodeficiency virus 
infection, and were evaluated for possible PCP during prophylaxis with aerosolized pentamidine. 
No transbronchial biopsies were performed. In 32 of 34 cases, a diagnosis of PCP could be 
excluded because of other definite diagnoses or improvement during the follow-up. Despite 
negative results of an examination of their BAL fluid, two patients received empirical treatment 
that was active against PCP; these patients were regarded as possibly having undiagnosed PCP. 
Thus, the negative predictive value of BAL alone was at least 94% (32 of 34 cases) in excluding a 
diagnosis of PCP during prophylaxis with aerosolized pentamidine. 
Although aerosolized pentamidine has been shown to be 
effective for primary and secondary prevention of Pneumo- 
cystis carinii pneumonia (PCP) in patients infected with hu- 
man immunodeficiency virus (HIV) [1-3], breakthrough 
PCP occurs despite prophylaxis in 8%-22% of these patients 
per year [2, 3]. A delay in diagnosis in these cases worsens 
the prognosis, as mortality due to PCP is associated with ad- 
vanced disease and respiratory failure [4]. When no P. carinii 
is detected in spontaneous or induced sputum, fiberoptic 
bronchoscopy with bronchoalveolar lavage (BAL) is the 
diagnostic procedure of choice; it is well tolerated and has a 
sensitivity of between 86% and 100% [5-7]. Transbronchial 
biopsy is associated with a higher risk of complications and 
does not substantially improve the overall yield in detection 
of P. carinii in patients who have received no prophylaxis [5, 
7]. Therefore, it has not been used in our institution as an 
initial procedure. However, a decrease in the diagnostic yield 
of BAL was recently reported in regard to patients receiving 
pentamidine prophylaxis, a finding that suggests the need for 
performance of transbronchial biopsy during bronchoscopy 
as well [7, 8]. We examined whether a diagnosis of PCP was 
missed during evaluation of high-risk patients who were re- 
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ceiving pentamidine prophylaxis and in whom no P. carinii 
had been detected by BAL and no transbronchial biopsy had 
been performed. The clinical outcome was prospectively an- 
alyzed on the basis of the assumption that undiagnosed and 
untreated PCP would progress and become clinically appar- 
ent during a 3-month follow-up. 
Methods 
Between September 1989 and March 1991 at our facility, 
we studied all patients with HIV infection who were under- 
going BAL for clinically suspected PCP while receiving pro- 
phylaxis with aerosolized pentamidine. All 34 consecutive 
cases in which BAL fluid was negative for P. carinii were 
prospectively followed for 3 months, and their clinical out- 
come was assessed. 
The clinical suspicion of PCP was based on certain factors: 
immunodeficiency, respiratory symptoms (cough and dys- 
pnea), fever, and/or evidence of infiltrates on a chest roent- 
genogram. Dyspnea was defined as shortness of breath with 
or without exertion, as reported by the patient. Fever was 
defined as a temperature of >37.8?C. All patients had re- 
ceived pentamidine (300 mg every 4 weeks, with use of the 
Respirgard II [Marquest Medical Products, Englewood, 
CO]) for at least 2 months before BAL was performed. 
Fiberoptic bronchoscopy was performed in a standardized 
way: the fiberoptic bronchoscope was advanced to the wedge 
position in the middle lobe or the lingula pulmonis sinistri, 
and four 50-mL boluses of 0.9% NaCl were sequentially in- 
stilled and withdrawn; the recovery of fluid ranged from 50% to 80%. In cases with localized pulmonary involvement, la- 
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vage was performed on multiple lung segments, including 
those with infiltrates detected by roentgenography. 
Transbronchial biopsy was not performed for any patient. 
The BAL fluid was examined for P. carinii with use of 
Giemsa and toluidine blue O stains as well as fluorescein- 
conjugated monoclonal antibodies. Gram stains, stains for 
acid-fast bacteria, and cultures for bacteria, fungi, mycobac- 
teria, and cytomegalovirus were also routinely done. 
For all subjects, a chest roentgenogram was obtained 
within 1 week prior to BAL; the roentgenogram was evalu- 
ated by staff radiologists and later verified by a pulmonolo- 
gist. The serum lactate dehydrogenase (LDH) level (normal 
values, 230-460 U/L) and arterial blood gas were assessed 
within 1 week of BAL, and the CD4 lymphocyte count, 
within 2 months. The alveolar-arterial oxygen tension gra- 
dient P(A-a)o2 was calculated by the simplified alveolar gas 
equation; the normal value (mm Hg) was derived as follows: 
(age[years]/2) + 5. 
Bronchitis or pneumonia was diagnosed by means of (1) 
bronchoscopic findings such as erythema or purulence in the 
airways, (2) exclusion of the presence of P. carinii, mycobac- 
teria, or other specific pathogens, and (3) radiological evi- 
dence of newly developed infiltrates (in cases of pneu- 
monia). 
A treatment active against PCP was defined as the adminis- 
tration for at least 1 week of any dose of trimethoprim-sulfa- 
methoxazole, dapsone, aerosolized or iv pentamidine 
(daily), or antitoxoplasmic agents. The patients continued 
the prophylaxis with aerosolized pentamidine (300 mg every 
4 weeks) after BAL was performed. 
To assess how many cases would have qualified for a pre- 
sumptive diagnosis of PCP if no BAL had been done, we 
determined which cases fulfilled the following four criteria 
[9]: (1) a history ofdyspnea with exertion or a nonproductive 
cough of recent onset (within the past 3 months); (2) evi- 
dence on a chest roentgenogram of diffuse bilateral intersti- 
tial infiltrates; (3) demonstration by arterial blood gas analy- 
sis of an arterial Po2 of <70 mm Hg or an increase in the 
P(A-a)o2; and (4) no evidence of bacterial pneumonia. 
Results 
During the study period of 19 months, 122 cases of PCP 
were diagnosed at our institution on the basis of examination 
of sputum or induced sputum (65 cases), BAL fluid (56), or 
pleural aspirate (1). In an additional 65 instances, BAL was 
done for suspected PCP but did not reveal P. carinii. Within 
this group, 33 patients (34 episodes) were receiving prophy- 
laxis with aerosolized pentamidine; the study population 
comprised these 33 patients who had 34 cases of clinically 
suspected PCP. 
The mean age of these patients (22 men and 11 women) 
was 35.7 years (range, 23-57 years). Seventeen were homo- 
sexuals, 10 were parenteral drug abusers, and six had no 
Table 1. Clinical presentation, findings on a roentgenogram of 
the chest, and laboratory values before performance of BAL 
(n = 34). 
Characteristic No. (%) of patients 
Fever 28 (82) 
Cough 29 (85) 
Dyspnea 17(50) 
Fever, cough, and dyspnea 12 (35) 
Findings on chest roentgenogram (n = 33): 
Diffuse infiltrates 19 (58) 
Lobar infiltrates 8 (24) 
No abnormalities 6 (18) 
Elevated LDH level (>460 U/L) (n = 33) 17 (52) 
PO2 of <70 mm Hg or elevated P(A-a)02 (n = 12) 7 (58) 
NOTE. LDH = lactate dehydrogenase in serum. 
identified risk factor for HIV infection. In all 34 cases AIDS 
was diagnosed before BAL was performed. Thirty patients 
had previously had PCP and were receiving secondary penta- 
midine prophylaxis, while four were given primary prophy- 
laxis. All were severely immunodeficient (the CD4 lympho- 
cyte count was <100/mm3 in 30 cases and <200/mm3 in all 
cases). Treatment was given with zidovudine in 26 cases and 
with didanosine in three, while no antiretroviral treatment 
was given in five cases. Symptoms, laboratory data, and 
roentgenographic findings were compatible with the clinical 
suspicion of PCP (table 1). The median duration of symp- 
toms before BAL was 3.4 weeks (range, 0-8 weeks). 
Based on the results of BAL, a diagnosis was made in 28 
cases (table 2). No diagnosis could initially be established in 
the remaining six cases; two of these patients were empiri- 
cally treated for PCP despite the fact that P. carinii was not 
identified in the BAL fluid. One of these patients received 
dapsone (100 mg/d), trimethoprim (900 mg/d), and antibi- 
otics because of concurrent Staphylococcus aureus pneumo- 
nia and was cured. The other received trimethoprim- 
sulfamethoxazole (75/15 mg/[kg d]), and his condition 
improved temporarily. Subsequently, however, he became 
febrile again and died after 2/2 months; the autopsy revealed 
generalized toxoplasmosis but no PCP. In the other 32 cases, 
no treatment active against P. carinii was given, and none of 
the patients developed PCP during the 3-month follow-up 
period. Therefore, the negative predictive value of BAL was 
at least 94% (32 of 34 cases) if the two patients who were 
treated for PCP were considered as possibly (although not 
evidently) having undiagnosed PCP. 
The final diagnoses in the 32 cases in which no treatment 
active against P. carinii was given included bronchitis (3 
cases), pneumonia (18), nontuberculous mycobacteriosis 
(7), Kaposi's sarcoma (4, of which 3 were concurrent with 
pneumonia), and cerebral toxoplasmosis, cytomegalovirus 
pneumonitis, and nonspecific interstitial pneumonitis (1 
each). Nontuberculous mycobacteriosis was detected by cul- 
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Table 2. Diagnoses made at the time of BAL and at the end of the 
3-month follow-up period. 
New diagnosis or clinical 
Diagnosis at the time of BAL aspects noted after follow-up 
(no. of patients) (no. of patients) 
Bronchitis or pneumonia (21 )* None 
Kaposi's sarcoma (4)* None 
Nontuberculous mycobacteriosis (4)t None 
Cytomegalovirus pneumonitis (1) None 
Nonspecific interstitial pneumonitis (1) None 
Unclear (6) Therapy for PCP given; clinical 
improvement (1 )" 
Therapy for PCP given; death 
after 2 /2 months; autopsy 
revealed generalized 
toxoplasmosis (1 ) 
Cerebral toxoplasmosis (1) 
Nontuberculous 
mycobacteriosis (3)t 
* In three cases both pneumonia and Kaposi's sarcoma were diagnosed. 
t These cases of mycobacterial infection were due to M. avium complex 
(4), M. kansasii (1), M. malmoense (1), and both M. avium complex and M. 
kansasii (1); all cases were confirmed by cultural detection of the pathogens 
in specimens of the blood or from other organs. * Initial findings were reported as "possibly few cysts of P. carinii," but no 
cysts were seen in a later review; concurrent pneumonia due to Staphylococ- 
cus aureus was treated with additional antibiotics. * These two patients were empirically treated for PCP and regarded as 
possibly having undiagnosed PCP. 
ture in 3 of 6 cases in which no acid-fast bacilli were detected 
in BAL fluid and the etiology was initially unclear. The slow 
cultural growth of nontuberculous mycobacteria was thus an 
important factor contributing to the delayed diagnosis for 
these patients. 
Elevation of serum LDH occurred in all disease categories: 
9 (43%) of 21 cases of bronchitis or pneumonia; 3 (43%) of 7 
cases of nontuberculous mycobacteriosis; and 2 (50%) of 4 
cases of Kaposi's sarcoma. 
Four patients died during follow-up. An autopsy was per- 
formed on three (including the patient with generalized tox- 
oplasmosis) and revealed no evidence of PCP. The fourth 
patient had been treated for bacterial pneumonia following 
BAL and recovered clinically but died 2 months later of an 
unknown cause. 
Discussion 
In this prospective study of patients evaluated for sus- 
pected PCP while receiving pentamidine prophylaxis, the 
negative predictive value of BAL was at least 94%. Although 
all patients in this series were at high risk for PCP [10-12] 
because of previously diagnosed AIDS and severe immuno- 
deficiency, as well as their symptoms and the clinical and 
laboratory findings (table 1), no cases of undiagnosed PCP 
were positively identified during the follow-up. The decision 
to treat two patients for PCP despite the negativity of BAL 
fluid for P. carinii was made by their physicians; these pa- 
tients were considered as possibly having undiagnosed PCP 
despite the fact that pneumonia of a different etiology might 
have responded to the treatment. Our study confirms the 
finding that aerosolized pentamidine does not substantially 
decrease the diagnostic yield of BAL in detection of P. carinii 
[13]. Previous retrospective studies of small numbers of pa- 
tients, in which yields of only 50%-62% were reported [7, 8], 
directly compared results of examinations of BAL and trans- 
bronchial biopsy specimens but did not use fluorescein-con- 
jugated monoclonal antibodies (which may increase the sen- 
sitivity of BAL [14]). Comparisons of the morphologic 
detection of P. carinii and the subsequent development of 
disease, as made in our study, are limited by the difference in 
study designs. However, the negative predictive value of 
BAL was validated by our patients' clinical course, which 
supports the practice of employing BAL without transbron- 
chial biopsy in all cases in which spontaneous or induced 
sputum cannot be obtained or does not allow a definite diag- 
nosis. Transbronchial biopsy employed in addition to BAL 
would implicate an unnecessary risk of pneumothorax and 
bleeding [15, 16] and should remain a second-step diagnos- 
tic tool in cases requiring further evaluation. 
The decision to assess the clinical outcome 3 months after 
BAL for development of PCP was based on the natural his- 
tory of PCP [ 17]; we assumed that untreated PCP would fur- 
ther progress within this time. For patients who received no 
prophylaxis for PCP, even a shorter follow-up (6 weeks) en- 
abled us to differentiate between PCP and other respiratory 
conditions [12]. 
When the results of screening with BAL were disregarded 
and only the symptoms and signs noted before BAL were 
considered, four patients (12%) met the criteria for presump- 
tive diagnosis of PCP [9]. Without performance of BAL, 
these cases would have been misdiagnosed as PCP and the 
patients would have been unnecessarily treated. Among pa- 
tients in every disease category, elevation of serum LDH was 
found in 43%-50%, thus confirming that LDH is a sensitive 
[12] but rather nonspecific predictor of PCP. These findings 
illustrate the limitations of algorithms designed to predict 
PCP [12] and emphasize the value of the detection of P. 
carinii during the diagnostic process. Because of the high 
toxicity of the agents presently used in treatment regimens 
for PCP [18, 19], the avoidance of unnecessary therapy is 
important in maintaining the patients' quality of life. 
Before BAL was performed, we were able to obtain sponta- 
neous or induced sputum from 22 of the patients studied. 
The performance of BAL for these patients was indicated by the finding that the sputum was contaminated or nondiag- 
nostic, thereby necessitating further diagnostic efforts. De- 
spite its slightly lower sensitivity for detection of PCP, exami- 
nation of induced sputum should nevertheless represent the 
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first diagnostic step for immunodeficient patients with respi- 
ratory symptoms. 
Our study shows that clinical findings characteristic of 
PCP can originate from miscellaneous diseases, including 
bacterial infections of the lower respiratory tract (62% of all 
cases). Haemophilus influenzae, S. aureus, and pneumococci 
were among the bacterial pathogens isolated in our study and 
should be considered with respect to not only the diagnostic 
workup but also the choice of antibiotics for HIV-infected 
patients with respiratory infections [20]. Nontuberculous 
mycobacteriosis and Kaposi's sarcoma accounted for 21% 
and 12% of cases, respectively. While the proportion of cases 
of AIDS with tuberculosis or nontuberculous mycobacterio- 
sis is increasing [2 1], the detection of these mycobacteria still 
causes a diagnostic delay because of their slow cultural 
growth; more-rapid detection methods such as polymerase 
chain reaction or chromatography are needed to enable initia- 
tion of adequate treatment as early as possible [22]. 
In summary, for HIV-infected patients with pulmonary 
symptoms who are at risk for PCP, detection of P. carinii 
should definitely be attempted; however, BAL fluid that is 
shown to contain no P. carinii during a period of prophylaxis 
with pentamidine is sufficiently reliable evidence for exclud- 
ing a diagnosis of PCP. A vigorous search for other causes of 
pulmonary disease is required for such patients, as an exact 
diagnosis is necessary for instituting adequate therapeutic 
measures for the wide spectrum of possible diseases. 
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